Gates Frontier Fund
VC Fund
Denver, United States
Gates Frontier Fund is an investment fund.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries Gates Frontier Fund invests in
EnergyBiotechnologyRoboticsTherapeuticsManufacturing
Stages Gates Frontier Fund invests in
Series BSeedSeries CSeries ASeries D
Countries Gates Frontier Fund invests in
United States
Investment Focus
Industry
- Energy 5 (19%)
- Biotechnology 5 (19%)
- Robotics 4 (15%)
- Therapeutics 4 (15%)
- Manufacturing 4 (15%)
Stage
- Series B 6 (22%)
- Seed 4 (15%)
- Series C 4 (15%)
- Series A 3 (11%)
- Series D 3 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
LifeMine Therapeutics
|
Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $188M / Series E / Aug 06, 2026 | |
Cerevance
|
Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, thecompany generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders. | $20M / Series C / May 12, 2026 | |
Glydways
|
Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs. | $170M / Series C / Apr 14, 2026 | |
Cellares
|
Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $257M / Series D / Jan 28, 2026 | |
MindImmune Therapeutics
|
MindImmune Therapeutics is a pharmaceutical company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, including Alzheimer’s and Huntington’s disease, pain, and psychiatric disorders. It is increasingly clear that the central nervous system and the immune system are intimately integrated.Consequently, immune system dysfunction is a critical, often causative, factor in brain dysfunction. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs. | $15.2M / Series A / Nov 24, 2025 | |
|
Glydways
|
Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs. | $101.3M / Venture - Series Unknown / Sep 29, 2025 | |
Field AI
|
Field AI develops autonomy software that equips mobile robots with a universal, risk-aware brain. It offers Field Foundation Models™ (FFMs) that enable embodiment-agnostic operation across legged, wheeled, flying, and tracked platforms. The company’s technology empowers robots to work safely in dynamic, unmapped environments, without reliance onGPS, pre-programmed routes, or maps, operating fully at the edge in real-time. Robots using this software can be deployed across industries such as construction, energy, mining, agriculture, urban operations, manufacturing, power and utilities, and federal applications, among others. | $314M / Series A / Aug 20, 2025 | |
|
Field AI
|
Field AI develops autonomy software that equips mobile robots with a universal, risk-aware brain. It offers Field Foundation Models™ (FFMs) that enable embodiment-agnostic operation across legged, wheeled, flying, and tracked platforms. The company’s technology empowers robots to work safely in dynamic, unmapped environments, without reliance onGPS, pre-programmed routes, or maps, operating fully at the edge in real-time. Robots using this software can be deployed across industries such as construction, energy, mining, agriculture, urban operations, manufacturing, power and utilities, and federal applications, among others. | $91M / Venture - Series Unknown / Aug 20, 2025 | |
Mainspring Energy
|
Mainspring Energy is engineering advanced technology to revolutionize the way electricity is generated and delivered | $258M / Series F / Apr 14, 2025 | |
Lumotive
|
Lumotive is a Seattle-based startup company developing high performance, solid-state lidar for autonomous systems in the automotive, UAV, robotics and related industries. The company's revolutionary beam-steering technology leverages Liquid Crystal Metasurfaces (or LCMs) implemented in mature semiconductor manufacturing processes to deliversmall, inexpensive 3D perception systems with unprecedented performance and reliability. For more information, visit us at www.lumotive.com. | $59M / Series B / Feb 19, 2025 | |
| See all 27 investments → | |||
Co-Investors
Khosla Ventures
10 deals together
Google Ventures
5 deals together
General Catalyst
4 deals together
Lightstone Ventures
4 deals together
ACS, Actividades de Construcción y Servicios
3 deals together
MetaVC Partners
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Hardware Investors
40,144 investors
Energy Investors
25,111 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
SaaS VC Funds
61,208 investors
FAQ
What does Gates Frontier Fund invest in?
Gates Frontier Fund invests primarily in Energy, Biotechnology and Robotics startups, most often at Series B and Seed stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Gates Frontier Fund last invest?
The most recent investment recorded for Gates Frontier Fund closed in Aug 2026. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
